UPF 648

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: UPF 648
• 英文别名: (1s,2s)-2-(3,4-Dichlorobenzoyl)cyclopropanecarboxylic Acid；(1S,2S)-2-(3,4-dichlorobenzoyl)cyclopropane-1-carboxylic acid
• 化学式: C₁₁H₈Cl₂O₃
• 分子量: 259.089
• InChiKey: ZBRKMOHDGFGXLN-BQBZGAKWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  UPF 648 在 N,N'-羰基二咪唑 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 42.0h， 生成 [(2R,3R,4S,5R,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]methyl(1S,2S)-2-[(3,4 dichlorophenyl)carbonyl]cyclopropane-1-carboxylate
  参考文献：
  名称：

  Glycoside derivatives of 2-(3,4-dichlorobenzoyl)-cycopropane-1-carboxylic acid

  摘要：

  式I化合物：其中R是糖苷残基，该糖苷残基任选地具有一个或多个羟基，这些羟基被C1-C4烷基或酰基团烷基化或酰基化，是长效的犬尿氨酸3-单加氧酶（KMO）抑制剂和强效的谷氨酸（GLU）释放抑制剂。

  公开号：

  EP1475385A1
• 作为产物：
  描述：

  (+)-Dimethyl trans-cyclopropanedicarboxylate 在 aluminum (III) chloride 、 氢氧化钾 、 草酰氯 、 水 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 30.5h， 生成 UPF 648
  参考文献：
  名称：

  Glycoside derivatives of 2-(3,4-dichlorobenzoyl)-cycopropane-1-carboxylic acid

  摘要：

  式I化合物：其中R是糖苷残基，该糖苷残基任选地具有一个或多个羟基，这些羟基被C1-C4烷基或酰基团烷基化或酰基化，是长效的犬尿氨酸3-单加氧酶（KMO）抑制剂和强效的谷氨酸（GLU）释放抑制剂。

  公开号：

  EP1475385A1

文献信息

• [EN] KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE KYNURÉNINE-3-MONOOXYGÉNASE, COMPOSITIONS PHARMACEUTIQUES, ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：CHDI FOUNDATION INC

  公开号：WO2013151707A1

  公开（公告）日：2013-10-10

  Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising the same and methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof described herein, effective to reduce signs or symptoms of the disease or disorder. These diseases include neurodegenerative disorders such as Huntington's disease.

  本文描述了某些化合物，或其药学上可接受的盐或前药、含有这些化合物的药物组合物以及治疗对抑制KMO活性有反应的某些疾病和障碍患者的方法，这些方法包括向此类患者施用至少一种本文所述的化合物，或其药学上可接受的盐或前药的有效量，以减轻疾病或障碍的体征或症状。这些疾病包括亨廷顿病等神经退行性疾病。
• Chiral cyclopentadienyl Rh^III-catalyzed enantioselective cyclopropanation of electron-deficient olefins enable rapid access to UPF-648 and oxylipin natural products
  作者：Coralie Duchemin、Nicolai Cramer

  DOI：10.1039/c8sc05702h

  日期：——

  Chiral cyclopentadienyl RhIII complexes efficiently catalyze enantioselective cyclopropanations of electron-deficient olefins with N-enoxysuccinimides as the C1 unit. Excellent asymmetric inductions and high diastereoselectivities can be obtained for a wide range of substrate combinations. The reaction proceeds under mild conditions without precautions to exclude air and water. Moreover, the synthetic

  手性环戊二烯基 Rh III配合物可有效催化以N-烯氧基琥珀酰亚胺为 C1 单元的缺电子烯烃的对映选择性环丙烷化反应。对于广泛的底物组合可以获得优异的不对称诱导和高非对映选择性。反应在温和条件下进行，无需采取排除空气和水的措施。此外，通过氧脂素天然产物家族成员和 KMO 抑制剂 UPF-648 的简明合成，证明了所开发方法的合成实用性。
• KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：CHDI FOUNDATION, INC.

  公开号：US20150057238A1

  公开（公告）日：2015-02-26

  Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化合物，或其药学上可接受的盐或前药。还提供了包含至少一种化合物或其药学上可接受的盐或前药及一种或多种药学上可接受的载体的制药组合物。本文描述了治疗对KMO活性抑制有反应的某些疾病和障碍的患者的方法，包括向这些患者施用至少一种本文所述的化合物或其药学上可接受的盐或前药的有效量，以减少疾病或障碍的症状。这些疾病包括神经退行性疾病，如亨廷顿病。本文还描述了治疗方法，包括将至少一种本文所述的化合物或其药学上可接受的盐或前药作为单一活性剂施用，或将至少一种本文所述的化合物或其药学上可接受的盐或前药与一种或多种其他治疗剂联合施用。还提供了筛选能够抑制KMO活性的化合物的方法。
• Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
  申请人：CHDI Foundation, Inc.

  公开号：US10442782B2

  公开（公告）日：2019-10-15

  Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化合物或其药学上可接受的盐或原药。还提供了包含至少一种本文所述化合物或其药学上可接受的盐或原药以及一种或多种药学上可接受的载体的药物组合物。描述了治疗对抑制 KMO 活性有反应的某些疾病和失调患者的方法，其中包括向此类患者施用一定量的本文所述的至少一种化合物或其药学上可接受的盐或原药，以有效减少疾病或失调的体征或症状。这些疾病包括神经退行性疾病，如亨廷顿氏病。还描述了治疗方法，包括将本文所述的至少一种化合物或其药学上可接受的盐或原药作为单一活性剂给药，或将本文所述的至少一种化合物或其药学上可接受的盐或原药与一种或多种其它治疗剂联合给药。还提供了筛选能够抑制 KMO 活性的化合物的方法。
• Treatment of aneurysms
  申请人：Georgia State University Research Foundation, Inc.

  公开号：US11376248B2

  公开（公告）日：2022-07-05

  The present invention provides methods for detecting and/or treating a subject having an aneurysm or at risk for developing an aneurysm. It has been discovered that a key metabolite of the kynurenine (Kyn) pathway, a major route for the metabolism of essential amino acid tryptophan (Trp) into nicotinamide adenine dinucleotide (NAD+), plays a critical role in the formation of aneurysms, for example abdominal aortic aneurysms. In particular, it has been discovered that 3-Hydroxyanthranilic acid (3-HAA), a product of kynureninase (KYNU), plays a causative role in the formation of aneurysms by, for example exerting pro-inflammatory effects on vascular smooth muscle cells. It has further been discovered that elevated levels of 3-HAA are indicative of the presence and/or progression of an aneurysm, and 3-HAA levels correlate with the size (aortic diameter) of the aneurysm.

  本发明提供了检测和/或治疗患有动脉瘤或有罹患动脉瘤风险的受试者的方法。现已发现，犬尿氨酸（Kyn）途径的一种关键代谢物--将必需氨基酸色氨酸（Trp）代谢为烟酰胺腺嘌呤二核苷酸（NAD+）的主要途径--在动脉瘤（例如腹主动脉瘤）的形成中起着关键作用。特别是，研究发现，3-羟基氨基苯甲酸（3-HAA）是犬尿苷酶（KYNU）的产物，通过对血管平滑肌细胞产生促炎作用等方式，在动脉瘤的形成过程中起着致病作用。研究进一步发现，3-HAA 水平的升高表明动脉瘤的存在和/或发展，3-HAA 水平与动脉瘤的大小（主动脉直径）相关。